Warning: Undefined variable $zfal in C:\Inetpub\vhosts\kidney.de\httpdocs\mlpefetch.php on line 525
Deprecated: str_replace(): Passing null to parameter #3 ($subject) of type array|string is deprecated in C:\Inetpub\vhosts\kidney.de\httpdocs\mlpefetch.php on line 525
Warning: Undefined variable $sterm in C:\Inetpub\vhosts\kidney.de\httpdocs\mlpefetch.php on line 530
Warning: Undefined variable $sterm in C:\Inetpub\vhosts\kidney.de\httpdocs\mlpefetch.php on line 531
English Wikipedia
Nephropedia Template TP (
Twit Text
DeepDyve Pubget Overpricing |
lüll Guidance of antibiotic therapy with procalcitonin in lower respiratory tract infections: insights into the ProHOSP study Schuetz P; Christ-Crain M; Albrich W; Zimmerli W; Mueller BVirulence 2010[Mar]; 1 (2): 88-92In the recently published ProHOSP trial, we investigated the safety and external validity of procalcitonin (PCT) guidance for antibiotic therapy in patients with different severities of lower respiratory tract infections, mainly pneumonia. In this addendum, we aim to extend the initial report by reinforcing the rational of the PCT algorithm and by presenting more detailed data on antibiotic therapy in different severities of infection. In milder, mostly viral respiratory infections (i.e. acute or chronic bronchitis) initial prescription of antibiotics was markedly reduced by PCT guidance because PCT remained low in most patients. In pneumonia, PCT showed a severity-dependent increase and highest levels in patients with positive blood cultures. Thus, the main effect in pneumonia was a severity- and bacteremia-adapted reduction of the duration of antibiotic courses. In lower respiratory tract infections, PCT guidance had a differential effect on antibiotic exposure depending on the underlying type and severity of respiratory tract infection.|Anti-Bacterial Agents/adverse effects/*therapeutic use[MESH]|Bacterial Infections/*drug therapy[MESH]|Calcitonin Gene-Related Peptide[MESH]|Calcitonin/adverse effects/*therapeutic use[MESH]|Humans[MESH]|Practice Guidelines as Topic[MESH]|Protein Precursors/adverse effects/*therapeutic use[MESH]|Respiratory Tract Infections/*drug therapy[MESH] |